Time to Take Your Medicines, Seriously

Ocular Surface

Volumn 14, Issue 3, 2016, Pages 410-415

  Novack, Gary D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG EFFICACY; ELECTROMAGNETIC RADIATION; EXPIRATION DATE; HUMAN; LETTER; MEDICATION COMPLIANCE; MEDICATION ERROR; OPHTHALMOLOGY; PREGNANCY OUTCOME; DISEASE MANAGEMENT; EUROPE; EYE DISEASE; PUBLICATION;

DISEASE MANAGEMENT; EUROPE; EYE DISEASES; HUMANS; OPHTHALMOLOGY; PERIODICALS AS TOPIC;

EID: 84978488568     PISSN: 15420124     EISSN: 19375913     Source Type: Journal    
DOI: 10.1016/j.jtos.2016.05.003     Document Type: Letter

References (42)

1. 1 Urquhart, J., Time to take our medicines, seriously. Pharm Weekbl, 1992, 127769–127776.
2. 2 Glover, F.F., Dispenser for pharmaceuticals having patient compliance monitor apparatus: Alza Corporation. 1977.
3. 3 Kass, M.A., Meltzer, D.W., Gordon, M., et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 101 (1986), 515–523.
4. 4 Kass, M.A., Gordon, M., Morley, R.E., et al. Compliance with topical timolol treatment. Am J Ophthalmol 103 (1987), 188–193.
5. 5 Blackwell, B., Treatment adherence. Br J Psychiatry, 1976, 129513–129531.
6. 6 Susanna, R. Jr., De Moraes, C.G., Cioffi, G.A., Ritch, R., Why do people (still) go blind from glaucoma?. Transl Vis Sci Technol, 4, 2015, 1.
7. 7 Grant, W.M., Burke, J.F. Jr., Why do some people go blind from glaucoma?. Ophthalmology, 1982, 89991–89998.
8. 8 Novack, G.D., Pipeline: Treatment adherence in ophthalmology and astrophysics. Ocul Surf 8 (2010), 91–95.
9. 9 Vrijens, B., De Geest, S., Hughes, D.A., et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73 (2012), 691–705.
10. 10 Fischer, M.A., Stedman, M.R., Lii, J., et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 25 (2010), 284–290.
11. 11 Blaschke, T.F., Osterberg, L., Vrijens, B., Urquhart, J., Adherence to medications: Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Ann Rev Pharm Toxicol, 2011, 52275–52301.
12. 12 Stone, J.L., Robin, A.L., Novack, G.D., et al. An objective evaluation of eye-drop instillation in glaucoma patients. Arch Ophthalmol 127 (2009), 732–736.
13. 13 Anonymous, Early Refill Edits on Topical Ophthalmic Products. 2013.
14. 14 Anonymous, Health Insurance – Prescription Eye Drops – Refills. 2013.
15. 15 Pasquale, L.R., Prostaglandin-associated periorbitopathy. Cataract Refract Surg Today, 2011, 24–28.
16. 16 Nakakura, S., Yamamoto, M., Terao, E., et al. Prostaglandin-associated periorbitopathy in latanoprost users. Clin Ophthalmol, 2014, 951–956.
17. 17 Taketani, Y., Yamagishi, R., Fujishiro, T., et al. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Invest Ophthalmol Vis Sci 55 (2014), 1269–1276.
18. 18 Novack, G.D., Muir, K.W., Newman-Casey, P.A., Robin, A.L., Ocular hypotensive medications: adherence and performance. Shaarawy, T.M., Sherwood, M.B., Hitchings, R.A., Crowston, J.G., (eds.) Glaucoma, 2014, Elsevier, Saunders, London, 521–524.
19. 19 Novack, G.D., Moyer, E., Pipeline: Where do unused medications go when they die?. Ocul Surf 11 (2013), 139–142.
20. 20 Novack, G.D., Pipeline: Can I use those eyedrops after the expiration date?. Ocul Surf 13 (2015), 169–173.
21. 21 Osterberg, L.G., Urquhart, J., Blaschke, T.F., Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther 88 (2010), 457–459.
22. 22 Novack, G.D., Stamer, W.D., The “T” in JOPT. J Ocul Pharmacol Ther, 31, 2015, 129.
23. 23 Vrijens, B., Urquhart, J., Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 55 (2005), 616–627.
24. 24 Munro, S.A., Lewin, S.A., Smith, H.J., et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med, 4, 2007, e238.
25. 25 Hygeine NYCDoHaM, Tuberculosis Annual Summary. 2014.
26. 26 Stancil, S.L., Miller, M., Briggs, H., et al. Contraceptive provision to adolescent females pprescribed teratogenic medications. Pediatrics, 137(1), 2016 Jan, 10.1542/peds.2015-1454.
27. 27 Vrijens, B., Urquhart, J., Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther 95 (2014), 617–626.
28. 28 Vrijens, B., An introduction to adherence research. Elseviers, M., (eds.) Drug Utilization Research: Methods and Applications, 2016, John Wiley & Sons, New York, NY, 355–360.
29. 29 Robin, A.L., Novack, G.D., Covert, D.W., et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 144 (2007), 533–540.
30. 30 Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al., Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002), 701–713.
31. 31 Lichter, P.R., Musch, D.C., Gillespie, B.W., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 (2001), 1943–1953.
32. 32 Marin, D., Bazeos, A., Mahon, F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28 (2010), 2381–2388.
33. 33 Bhatia, S., Landier, W., Shangguan, M., et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol 30 (2012), 2094–2101.
34. 34 Paterson, D.L., Swindells, S., Mohr, J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med, 2000, 13321–13330.
35. 35 Geisler, W.M., Uniyal, A., Lee, J.Y., et al. Azithromycin versus Doxycycline for urogenital Chlamydia trachomatis infection. N Engl J Med 373 (2015), 2512–2521.
36. 36 Okeke, C.O., Quigley, H.A., Jampel, H.D., et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology 116 (2009), 2286–2293.
37. 37 Konstas, A.G., Tsironi, S., Georgiadou, I., et al. A One-Year Randomized Trial Investigating the Value Of an Intervention to Enhance Adherence in Newly-Diagnosed Glaucoma Patients Receiving Prostaglandin Monotherapy and in Patients Who Are Candidates for Adjunctive Therapy. Invest Ophthalmol Vis Sci, 50, 2009 ARVO E-Abstract 2477.
38. 38 Demonceau, J., Ruppar, T., Kristanto, P., et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. Drugs 73 (2013), 545–562.
39. 39 Hahn, S.R., Friedman, D.S., Quigley, H.A., et al. Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma. Ophthalmology 117 (2010), 1339–1347.
40. 40 Vrijens, B., Vincze, G., Kristanto, P., et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336:7653 (2008), 1114–1117.
41. 41 Novack, G.D., Ophthalmic drug delivery: Development and Regulatory Considerations. Clin Pharmacol Ther 85 (2009), 539–543.
42. 42 Novack, G.D., New horizons in glaucoma drug delivery. Glaucoma Today 12 (2014), 42–44.